These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 15843572

  • 1. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity.
    Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO.
    J Immunol; 2005 May 01; 174(9):5706-12. PubMed ID: 15843572
    [Abstract] [Full Text] [Related]

  • 2. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
    Livingston PO, Hood C, Krug LM, Warren N, Kris MG, Brezicka T, Ragupathi G.
    Cancer Immunol Immunother; 2005 Oct 01; 54(10):1018-25. PubMed ID: 15926079
    [Abstract] [Full Text] [Related]

  • 3. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
    Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP.
    J Immunol; 2016 Sep 01; 197(5):1762-75. PubMed ID: 27474078
    [Abstract] [Full Text] [Related]

  • 4. The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo.
    Imai M, Hwang HY, Norris JS, Tomlinson S.
    Immunology; 2004 Mar 01; 111(3):291-7. PubMed ID: 15009429
    [Abstract] [Full Text] [Related]

  • 5. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B, Ma ZW, Li H, Xu GL, Zheng P, Zhu B, Wu YZ, Zou Q.
    Clin Immunol; 2008 Aug 01; 128(2):155-63. PubMed ID: 18502181
    [Abstract] [Full Text] [Related]

  • 6. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.
    Hernández AM, Rodríguez N, González JE, Reyes E, Rondón T, Griñán T, Macías A, Alfonso S, Vázquez AM, Pérez R.
    J Immunol; 2011 Mar 15; 186(6):3735-44. PubMed ID: 21300821
    [Abstract] [Full Text] [Related]

  • 7. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G, Cappello S, Yi SS, Canter D, Spassova M, Bornmann WG, Danishefsky SJ, Livingston PO.
    Vaccine; 2002 Jan 15; 20(7-8):1030-8. PubMed ID: 11803062
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J, Jurlander J, Pedersen MW.
    Br J Haematol; 2013 Oct 15; 163(2):182-93. PubMed ID: 23927424
    [Abstract] [Full Text] [Related]

  • 11. Carbohydrate antigens as targets for active specific immunotherapy.
    Ragupathi G.
    Cancer Immunol Immunother; 1996 Nov 15; 43(3):152-7. PubMed ID: 9001568
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition.
    Goswami MT, Reka AK, Kurapati H, Kaza V, Chen J, Standiford TJ, Keshamouni VG.
    Oncogene; 2016 Apr 14; 35(15):1888-98. PubMed ID: 26148233
    [Abstract] [Full Text] [Related]

  • 14. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.
    Ragupathi G, Coltart DM, Williams LJ, Koide F, Kagan E, Allen J, Harris C, Glunz PW, Livingston PO, Danishefsky SJ.
    Proc Natl Acad Sci U S A; 2002 Oct 15; 99(21):13699-704. PubMed ID: 12359877
    [Abstract] [Full Text] [Related]

  • 15. TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms.
    Verma B, Jain R, Caseltine S, Rennels A, Bhattacharya R, Markiewski MM, Rawat A, Neethling F, Bickel U, Weidanz JA.
    J Immunol; 2011 Mar 01; 186(5):3265-76. PubMed ID: 21282517
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
    Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP.
    J Immunol; 2009 Jul 01; 183(1):749-58. PubMed ID: 19535640
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Complement-dependent in vitro cytotoxicity against autologous invasive bladder tumor cells in humans. Evaluation of the possible role of naturally-occurring antibodies in complement-dependent cytotoxicity.
    Jacobsen F.
    Acta Pathol Microbiol Scand C; 1981 Oct 01; 89(5):297-302. PubMed ID: 7315361
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.